3-(4-甲酰基苯基)丙酸乙酯 | 445483-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(4-甲酰基苯基)丙酸乙酯
• 中文别名: 3-(4-甲酰基苯基)丙酸甲酯
• 英文名称: 3-(4-formyl-phenyl)-propionic acid ethyl ester
• 英文别名: ethyl 3-(4-formylphenyl)propanoate；ethyl 3-(4-formyl-phenyl)propanoate
• CAS: 445483-72-7
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: KMLCMKXDMYDBMX-UHFFFAOYSA-N

物化性质

• 沸点：
  317.9±17.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319
• 储存条件：
  温度：2-8°C，存储环境：惰性气体

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  对溴苯丙酸乙酯	3-(4-bromo-phenyl)-propionic acid ethyl ester	40640-98-0	C11H13BrO2	257.127

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  3-(4-甲酰基苯基)丙酸	4-formyldihydrocinnamic acid	34961-64-3	C10H10O3	178.188
  3-(4-(羟基甲基)苯基)丙酸乙酯	ethyl 3-[4-(hydroxymethyl)phenyl]propanoate	107859-98-3	C12H16O3	208.257
  ——	ethyl 3-[4-(bromomethyl)phenyl]propanoate	56703-35-6	C12H15BrO2	271.154
  4-(3-羟基丙基)苯甲醛	4-(3-hydroxypropyl)benzaldehyde	81121-62-2	C10H12O2	164.204

反应信息

• 作为反应物：
  描述：

  3-(4-甲酰基苯基)丙酸乙酯 在 哌啶 、 乙醇 、 N,N'-羰基二咪唑 、 sodium hydroxide 、 β-丙氨酸 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 3-[4-(1-amino-2,4-dicyanopyrido[1,2-a]benzimidazol-3-yl)phenyl]-N-methylpropanamide
  参考文献：
  名称：

  Inhibition of the cellular function of perforin by 1-amino-2,4-dicyanopyrido[1,2-a]benzimidazoles

  摘要：

  A high throughput screen showed the ability of a 1-amino-2,4-dicyanopyrido[1,2-a]benzimidazole analogue to directly inhibit the lytic activity of the pore-forming protein perforin. A series of analogues were prepared to study structure-activity relationships (SAR) for the this activity, either directly added to cells or released in situ by KHYG-1 NK cells, at non-toxic concentrations. These studies showed that the pyridobenzimidazole moiety was required for effective activity, with strongly basic centres disfavoured. This class of compounds was relatively unaffected by the addition of serum, which was not the case for a previous class of direct inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.05.013
• 作为产物：
  描述：

  ethyl 3-(4-formylphenyl)acrylate 在 platinum on carbon 氢气 作用下， 以 四氢呋喃 为溶剂， 生成 3-(4-甲酰基苯基)丙酸乙酯
  参考文献：
  名称：

  FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1609798B1

文献信息

• COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
  申请人：Wong Norman C.W.

  公开号：US20080188467A1

  公开（公告）日：2008-08-07

  The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

  本公开涉及化合物，这些化合物可用于调节载脂蛋白A-I（ApoA-I）的表达，以及它们用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关紊乱，例如，动脉粥样硬化。
• Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease
  作者：Obdulia Rabal、Juan A. Sánchez-Arias、Mar Cuadrado-Tejedor、Irene de Miguel、Marta Pérez-González、Carolina García-Barroso、Ana Ugarte、Ander Estella-Hermoso de Mendoza、Elena Sáez、Maria Espelosin、Susana Ursua、Tan Haizhong、Wu Wei、Xu Musheng、Ana Garcia-Osta、Julen Oyarzabal

  DOI：10.1021/acs.jmedchem.6b00908

  日期：2016.10.13

  Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer’s disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure-

  磷酸二酯酶5（PDE5）和组蛋白脱乙酰基酶（HDAC）的同时抑制最近已被证实是阿尔茨海默氏病（AD）潜在的新型治疗方法。为了进一步扩展这个概念，我们设计并合成了第一个化学作用的双作用PDE5和HDAC抑制剂系列，并验证了该系统的治疗方法。在实施基于结构和知识的方法之后，设计了初始命中并显示了其来验证我们的双重体外抑制假说。然后，寻求优化策略以获得适合体内的工具化合物在AD模型中进行测试。最初的命中被翻译成具有适当细胞功能反应（组蛋白乙酰化和cAMP / cGMP反应元件结合（CREB）磷酸化在纳摩尔范围内），可接受的治疗窗（> 1 log单位）和穿越血液的能力的分子–脑屏障，从而将7鉴定为体内概念验证测试的候选者（Cuadrado-Tejedor，M。Garcia-Barroso，C .；JA，Sánchez-Arias；俄克拉荷马州拉巴尔；梅德罗斯（Mederos），S .；乌加特（A.）佛朗哥（Franco，R
• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281397A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防癌症，包括NUT中线癌、Burkitt淋巴瘤、急性髓系白血病和多发性骨髓瘤；自身免疫或炎症性疾病或症状，以及败血症。
• Direct synthesis of ester-containing indium homoenolate and its application in palladium-catalyzed cross-coupling with aryl halide
  作者：Zhi-Liang Shen、Kelvin Kau Kiat Goh、Colin Hong An Wong、Yong-Sheng Yang、Yin-Chang Lai、Hao-Lun Cheong、Teck-Peng Loh

  DOI：10.1039/c0cc05597b

  日期：——

  An efficient method for the synthesis of ester-containing indium homoenolate via a direct insertion of indium into beta-halo ester in the presence of CuI/LiCl was described. The synthetic utility of the indium homoenolate was demonstrated by palladium-catalyzed cross-coupling with aryl halides in DMA with wide functional group compatibility.

  描述了一种通过在CuI / LiCl存在下将铟直接插入β-卤代酯来合成含酯的均烯酸铟酯的有效方法。钯催化的与芳基卤化物在DMA中具有宽泛的官能团相容性的交叉偶联证明了烯丙基铟的合成效用。
• [EN] HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF<br/>[FR] DÉRIVÉS DE L'ACIDE HYPOPHOSPHOREUX AYANT UNE ACTIVITÉ ANTIHYPERALGIQUE ET LEURS APPLICATIONS BIOLOGIQUES
  申请人：UNIV PARIS DESCARTES

  公开号：WO2012156931A1

  公开（公告）日：2012-11-22

  The invention relates to hypophosphorous acid derivatives of formula (I) wherein - X is H or OH, - R represents one or several radicals R1-R5, identical or different, two of R1-R5 optionally occupying the same position on the phenyl group, one to four of R1-R5 being H and the others being selected in the group comprising - 0-(CH2)n-COOH; - S-(CH2)n-COOH; -NH-(CH2)n-COOH; - 0-(CH,R') -COOH; -O- (CH2)n-OH; OR', -R' being a C1 -C3 alkyl radical;-OH; --COOH; halogen, particularly -F, - CI, -Br, -I, -CF3; -OCF3; -N02; -CH=CH-COOH; - -(CH2)n-COOH; O - (CH2)n- P03H2; O - (CF2)n- P03H2; O - (CH2)n- S03H; O - (CH2)n- CONHOH; O - (CH2)n-tetrazol; O - (CH2)n-hydroxyisoxazol - n = 1 to 5, preferably 1-3; said hypophosrous acid derivatives being diastereoisomers or enantiomers.

  该发明涉及式(I)的次磷酸衍生物，其中- X为H或OH，- R代表一个或几个基团R1-R5，相同或不同，R1-R5中的两个可以选择占据苯基上的同一位置，R1-R5中的一到四个为H，其余的选择自-0-(CH2)n-COOH；-S-(CH2)n-COOH；-NH-(CH2)n-COOH；-0-(CH,R')-COOH；-O-(CH2)n-OH；OR'，其中-R'为C1-C3烷基基团；-OH；-COOH；卤素，特别是-F，-Cl，-Br，-I，-CF3；-OCF3；-NO2；-CH=CH-COOH；-(CH2)n-COOH；O-(CH2)n-P03H2；O-(CF2)n-P03H2；O-(CH2)n-S03H；O-(CH2)n-CONHOH；O-(CH2)n-四唑；O-(CH2)n-羟基异噁唑-n=1至5，优选1-3；所述的次磷酸衍生物为对映异构体或对映体。